Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma

Clinical Trial ID NCT01489059

Rank	Title	Journal	Year	PubWeight™‹?›
1	At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy.	J Leukoc Biol	2013	1.90
2	Trial Watch: Immunostimulatory cytokines.	Oncoimmunology	2012	1.19
3	Pathways and therapeutic targets in melanoma.	Oncotarget	2014	1.17
4	Checkpoint modulation in melanoma: an update on ipilimumab and future directions.	Curr Oncol Rep	2013	0.94
5	Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander".	Toxins (Basel)	2014	0.92
6	The future of glioblastoma therapy: synergism of standard of care and immunotherapy.	Cancers (Basel)	2014	0.91
7	Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12.	Semin Oncol	2015	0.89
8	Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study.	J Immunother Cancer	2014	0.83
9	IL-21: a pleiotropic cytokine with potential applications in oncology.	J Immunol Res	2015	0.83
10	Tertiary Lymphoid Structures in Cancers: Prognostic Value, Regulation, and Manipulation for Therapeutic Intervention.	Front Immunol	2016	0.83
11	Targeting CD8+ T-cell tolerance for cancer immunotherapy.	Immunotherapy	2014	0.81